Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASCT vs conventional chemotherapy in high-risk lymphoplasmacytic lymphoma / Waldenström macroglobulinemia
ChiCTR-OIN-16008401Phase 3Recruiting
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- May 2016
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 3, randomised trial of autologous hematopoietic stem cells in Lymphoplasmacytic Lymphoma (LPL) and Waldenström macroglobulinemia (WM) (2 arms), sponsored by Institute of Hematology and Blood Diseases Hospital. Primary endpoint: progression-free survival. Started May 2016; status: recruiting.
02
Drugs
autologous hematopoietic stem cells
03
Conditions
Lymphoplasmacytic Lymphoma (LPL)Waldenström macroglobulinemia (WM)
Beyond the preview
Go deeper on ChiCTR-OIN-16008401.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-OIN-16008401.